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Myotonic dystrophy type 1 (DM1) is an inherited dis-
ease characterizedby the inability to relax contracted
muscles. Affected individuals carry large CTG expan-
sions that are toxic when transcribed. One possible
treatment approach is to reduce or eliminate tran-
scription of CTG repeats. Actinomycin D (ActD) is a
potent transcription inhibitor and FDA-approved
chemotherapeutic that binds GC-rich DNA with high
affinity. Here, we report that ActD decreased CUG
transcript levels in a dose-dependent manner in
DM1 cell and mouse models at significantly lower
concentrations (nanomolar) compared to its use as
ageneral transcription inhibitor or chemotherapeutic.
ActD also significantly reversed DM1-associated
splicing defects in a DM1 mouse model, and did so
within the currently approved human treatment
range. RNA-seq analyses showed that low concen-
trations of ActD did not globally inhibit transcription
in a DM1 mouse model. These results indicate that
transcription inhibition of CTG expansions is a prom-
ising treatment approach for DM1.
INTRODUCTION
Myotonic dystrophy (DM), the most common form of adult onset
muscular dystrophy, is a disease characterized by (but not
limited to) myotonia, muscle wasting, insulin resistance, cardio-
myopathy, and cognitive dysfunctions (Ranum and Cooper,
2006; Cho and Tapscott, 2007). DM has two clinical manifesta-
tions: type 1 and type 2 (DM1 and DM2). DM1 is caused by an
inherited expansion of CTG repeats in the 30 UTR of the DMPK
gene (Harley et al., 1992; Mahadevan et al., 1992). Unaffected
individuals have between 5 and 35 CTG repeats, while those af-
flicted with DM1 have more than 50 and can have up to thou-
sands of repeats (reviewed in O’Rourke and Swanson, 2009).
When transcribed into RNA, the CUG repeats serve as binding2386 Cell Reports 13, 2386–2394, December 22, 2015 ª2015 The Ausites for RNA-binding proteins, including the MBNL family of
splicing factors (Miller et al., 2000). By binding to and aggre-
gating with the CUG repeats, MBNL proteins are effectively
‘‘sequestered’’ away from performing their canonical functions
(Ho et al., 2004; reviewed in Osborne and Thornton, 2006).
Consistent with this model, in vivo fluorescent probing experi-
ments of expanded CUG repeats demonstrated that they form
nuclear aggregates, or foci, containing MBNL proteins (Fardaei
et al., 2002; Ho et al., 2005).
Members of the MBNL family regulate the alternative splicing
of more than 100 different transcripts, and are also involved in
RNA localization and processing events (reviewed in Konieczny
et al., 2014; Echeverria and Cooper, 2012). Some mRNAs that
aremis-spliced inDM1, including insulin receptor (INSR), cardiac
troponin T (TNNT2), and muscle-specific chloride channel
(CLCN1), correspond directly or are linked to symptoms experi-
enced by DM1 patients—insulin insensitivity, cardiac defects,
and myotonia, respectively (Savkur et al., 2001; Philips et al.,
1998; Mankodi et al., 2002). Although there is currently no treat-
ment, approaches are under development that reduce or elimi-
nate CUG:MBNL aggregates using small molecules, antisense
oligonucleotides, and peptides (Warf et al., 2009; Arambula
et al., 2009; Nakamori et al., 2011; Lee et al., 2012; Wheeler
et al., 2012).More recently, studies have indicated that smallmol-
ecules that interact with CTG-rich DNA reduce CUG RNA levels,
likely through transcription inhibition (Coonrod et al., 2013). The
latter finding prompted us to identify transcription inhibitors
that possess high affinity and specificity for CTG-rich DNA.
Actinomycin D (ActD) is a small molecule known to bind GC-
rich DNA and is naturally produced by Streptomyces bacteria
(Waksman and Woodruff, 1940). ActD is commonly used in
mRNA stability studies as a general transcription inhibitor, with
common protocols using final concentrations of 1–3 mM to
achieve global transcription inhibition (Bensaude, 2011; Perry
and Kelley, 1970). Importantly, it is also a potent anticancer
drug that has been approved by the US Food and Drug Adminis-
tration since 1964 for multiple tumor types under the brand name
Cosmogen. From a structural standpoint, ActD is a neutral mole-
cule comprised of a planar phenoxazone ringwith twocyclic pen-
tapeptides (Figure 1A), and binds double and single-strandedthors
AC D
B Figure 1. Biochemical Analysis of Actino-
mycin D Molecules Bound to CTG:CTG DNA
(A) Chemical structure of actinomycin D.
(B) Crystal structure of the 2:1 ActD-(ATGCTGCAT)
2 complex (re-imaged from Hou et al., 2002). ActD
molecules are in blue van der Waals representa-
tions, whereas DNA is shown in skeletal form.
Intercalation of the phenoxazone ring is observed
at both GpC steps, whereas pentapeptides remain
within the minor groove.
(C) Representative ITC isotherm for the interaction
between ActD and (CTG)4. Raw heats of reaction
versus time are embedded in the upper left of the
graph. The average thermodynamic binding pa-
rameters when fit with the sequential binding
model are K1 = (9 ± 6)*10
4, DH1 = (7 ± 6)*10
3 kcal/
mol, K2 = (2 ± 1)*10
6, DH2 = (3 ± 1)*104 kcal/mol.
(D) The lowest free energy structure of the (CTG)4
sequence (Reuter and Mathews, 2010).DNA (but notRNA) by intercalatingwithGpCsequenceswith high
specificity (M€uller and Crothers, 1968; Kamitori and Takusa-
gawa, 1992). A crystal structure by Hou and colleagues de-
monstrated that ActD binds CTG:CTG DNA with high affinity,
implicating the importance of the destabilized T:T mismatch for
binding (Hou et al., 2002; Liu and Chen, 1996). Close inspection
of this crystal structure reveals that the hydrophobic cyclic pen-
tapeptides of ActDmolecules are in proximity to each other when
bound to CTG DNA, possibly stabilizing the ActD:DNA complex
(Figure 1B). CTG:CTG DNA duplexes are a structural feature of
CTG triplet repeat expansions, often the result of DNA slippage
during replication (Chi and Lam, 2005; Petruska et al., 1996).
Collectively, these studies suggest that ActD may possess a
higher affinity for CTG repeat expansions compared to other
GC-containing targets in vivo.
In this study, we determined if ActD could reduce or even
completely reverse the toxic effects of transcribed CTG ex-
pansions in DM1. Using both cellular and mouse models, we
demonstrated that ActD reduces CTG transcript levels and ame-
liorates DM1-associated mis-splicing at low concentrations.
RNA sequencing (RNA-seq) analyses of a DM1 mouse model
further confirmed that the concentrations of ActD necessary
for significant CTG transcript reduction did not result in global
transcription inhibition and rescue mis-spliced events in DM1.Cell Reports 13, 2386–2394, DeRESULTS
Actinomycin D Interacts with CTG
DNA Repeats, but Not CUG RNA
Repeats
To ascertain whether ActD interacts with
CUG RNA in a similar capacity as with
CTG DNA, thermodynamic and stoichio-
metric properties associated with the for-
mation of ActD complexes with (CTG)4
and (CUG)4 sequences were determined
by isothermal titration calorimetry (ITC).
At least two different types of enthalpic
changes occur between (CTG)4 andActD (Figure 1C). Increasing ActD concentrations within the sys-
tem resulted in an initial endothermic reaction followed by an
exothermic reaction. The data were best fit with a sequential
binding model, indicating cooperativity between the two binding
events. The initial CTG-ActD interaction demonstrated a KD of
10 ± 7 mM, a considerably weaker affinity than the second inter-
action, which produced a KD value of 0.5 ± 0.3 mM, consistent
with the lowest free-energy structure of (CTG)4 containing two
ActDGpC sites (Figure 1D). Taken together with previous studies
that have indicated the need for a structural rearrangement of the
DNA for tight binding by ActD (Hou et al., 2002; Paramanathan
et al., 2012), these ITC data support an allosteric model of
ActD: DNA binding. Furthermore, as ActD did not produce an en-
thalpic change when titrated into the (CUG)4 RNA (data not
shown), it is clear that ActD is unable to bind CUG RNA in vitro
and thus unlikely that ActD preferentially binds CUG RNA in vivo.
Reduction of Transcripts Containing Expanded CUG
Repeats with Actinomycin D
Two DM1 cell models were tested to determine the ability of ActD
to reduce CUG repeat RNA levels. Previous studies demonstrated
that overexpression of 960 interrupted CUG repeats by transfec-
tion into HeLa cells recapitulates DM1 mis-splicing (Ho et al.,
2004; Warf et al., 2009). Northern blot analysis revealed that CUGcember 22, 2015 ª2015 The Authors 2387
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Figure 2. Actinomycin D Reduces CUG
Repeat Levels in DM1 Cell Models
(A and B) CUG repeat RNA levels after ActD
treatment in a DM1 HeLa cell system. Northern
blot analysis and quantification demonstrate a
significant decrease in CUG repeats at 5 nMwithin
the HeLa cells and a dose-dependent decrease
follows thereafter. GAPDH, a housekeeping gene,
is used as a control. In DM1 patient cells, amodest
increase in CUG repeats is observed after 6 nM,
and CUG levels persist at that amount from 7 nM
to 100 nM ActD (only data points up to 10 nM ActD
are shown). Asterisks indicate level of significance
(*p% 0.05, ***p% 0.001). Error bars represent SD.
(C) CUG ribonuclear foci formation in response to
ActD treatment in HeLa cells. Top row: nuclei of
untreated HeLa cells. DAPI staining of nucleus is
on far left and nuclear MBNL1 staining is in the
second column. These untreated cells were not
transfected with CUG repeats. Middle row: trans-
fection with CUG960 gives rise to ribonuclear foci in
HeLa cells. Aggregation of MBNL1 and CUG re-
peats observed in the second and third columns,
respectively. Bottom row: treatment with 10 nM
ActD in HeLa cells results in decreased number
and size of MBNL1 and CUG aggregates (second
and third columns), and reduction of MBNL
sequestration as evidence by reversion to more
diffuse staining (second column).RNA levels decreased by more than 50% (p = 0.002) with 5 nM
ActD treatment over 18 hr, decreased by 70% with 10 nM
ActD, and a dose-dependent decrease was observed from 10 to
20 nM ActD (Figure 2A). Over this range of ActD concentrations,
levels of the GAPDH transcript (used as a control) remained rela-
tively constant. To determine if ActD reduced endogenous CTG
repeat transcription, a DM1patient-derived fibroblast line contain-
ing over 2000 CTG repeats was tested (Chaouch et al., 2009). The
DM1patient-derivedcells responded toActDovera lowerconcen-
tration range compared to HeLa cells, with a dose-dependent
decrease in CUG RNA levels observed from 1 to 6 nM ActD treat-
ment over an 18 hr treatment (Figure 2B). CUG RNA levels were
reduced by 44%at 3 nM and 60%at 6 nM (p = 0.03). Interestingly,
a reproducible 20% increase in CUG RNA was observed around
7 nM treatment but was significantly lower than in untreated
DM1 cells. CUG repeat RNA remained constant from 7 nM to
> 100 nM ActD treatment (data not shown). Once again, GAPDH
control levels were unaffected by ActD levels in this concentration
range. The concentrations of ActD appeared to be mildly toxic to
HeLa cells at the concentrations tested, and very little to no toxicity
was observed in the DM1 patient-derived fibroblast line, as
confirmed by cell viability assays (data not shown).2388 Cell Reports 13, 2386–2394, December 22, 2015 ª2015 The AuthorsCUG Repeat Foci Formation Is
Reduced with Actinomycin D
Treatment
To directly demonstrate the effect of
ActD on MBNL1 sequestration, CUG
foci formation and nuclear MBNL1 local-
ization were examined in the HeLa cell
system in the presence or absence ofActD. MBNL1 antibody MB1a (4A8) was used to probe for
MBNL1 localization as previously described, and a CAG probe
was employed to bind CUG RNA (Holt et al., 2007). Untreated
HeLa cells (without CUG repeats) demonstrated diffuse locali-
zation of MBNL1 throughout the nucleus (Figure 2C, top row).
In the presence of CUG960, RNA foci were observed, and
MBNL1 staining demonstrated aggregation (Figure 2C, middle
row). Upon incubation with 10 nM ActD for 18 hr, we observed
a decrease in the number of foci per cell when compared to
the transfected controls (Figure 2C, bottom row). While most
cells treated with this ActD concentration still possessed
some nuclear foci, there was a 50% reduction observed in
the number of foci per nucleus (n = 66, p = 0.00002). Further-
more, treated cells demonstrated a 46% decrease in the num-
ber of large foci, when large foci were defined as greater than
2 mm3 (n = 66, p < 0.000025). Nuclear MBNL1 in treated cells
was more diffuse compared to untreated cells, despite the
persistence of several foci. Our observations of foci reduction
in the HeLa model and the reduction of CUG RNA in both cell
types motivated further investigations to determine if ActD
treatment could correct DM1 molecular pathology in a mouse
model.
ActinomycinDPartially RescuesMis-splicing ofMultiple
Events in a DM1 Mouse Model
The HSALR mouse model expresses 220 CUG repeats under the
human skeletal actin promoter (Mankodi et al., 2000). qRT-PCR
showed a significant reduction (p = 0.01) of the HSA transgene
mRNA in the HSALR mouse in response to a 5-day 0.025 mg/
kgActD treatment compared to PBS-treated controls (Figure 3A).
In contrast, mRNA levels of the endogenous Dmpk gene (which
does not possess long repeats in these transgenic mice) did not
decrease significantly upon ActD treatment (Figure 3B), suggest-
ing specificity for the repeat-containing HSA transgene.
Splicing rescue of two commonly examined, MBNL-regulated
transcripts was observed upon ActD treatment in a DM1 trans-
genic mouse model: the muscle-specific chloride ion channel
(Clcn1), the mis-splicing of this event is responsible for causing
the myotonia phenotype in HSALR mice, and the sarco/endo-
plasmic reticulum Ca2+ ATPase 1 (Atp2a1 or Serca1) (Mankodi
et al., 2002; Kimura et al., 2005). In Clcn1, ActD treatment with
either 0.125mg/kg or 0.25mg/kg over a 5-day treatment regimen
resulted in the robust rescue of Clcn1 splicing, as demonstrated
by an increase in the exclusion of exon 7a (Figure 3C, lanes 3 and
4). TheAtp2a1event also showedsignificantmis-splicing rescue.
In this event, treatment with ActD increased levels of exon 22 to
83% ± 10% at the highest dosage (Figure 3D, lanes 3 and 4).
Although the mis-splicing of these events never reached full
rescue, the observed rescue was significant at the highest dos-
ages. Toxicity was not observed within the mouse model over
this treatment range. Other important MBNL-regulated splicing
rescue events were characterized in response to ActD treatment,
includingMbnl1 (auto-regulates its ownexpression at the splicing
level), Vps39 (regulator of TGF-beta signaling), Nfix (a transcrip-
tion factor), andLdb3 (important inmembrane protein clustering).
All of these events also demonstrated partial or complete rescue
of mis-splicing (Figures 3F–3H). Collectively, these results
showed that ActD partially reversed an important portion of
DM1 molecular pathology.
ActD Does Not Globally Modify Expression Profiles of
Treated DM1 Mice
Because ActD has a well-characterized ability to bind DNA ubiq-
uitously at higher concentrations and induce global transcription
inhibition,wewanted to assessActD’s effects on transcript levels
at the low dosages used in these studies. Therefore, RNA-seq
analyses were performed on 0.125 mg/kg, and 0.25 mg/kg
ActD-treated HSALR mouse vastus muscle RNA. Only 4.3% of
genes were differentially expressed (p < 0.1) with 0.125 mg/kg
ActD treatment, compared to the untreated controls; a similarly
low proportion of genes were affected with the higher treatment
(0.25 mg/kg, 5.1%.) (Figure 4A). Approximately 3% of genes
decreased in expression with either dosage, possibly a direct
result of ActD-mediated transcriptional inhibition. Meanwhile,
about 2% of genes increased in expression with either dosage.
Collectively, these data demonstrated that ActD does not
broadly inhibit transcription within these treatment concentra-
tions, anddoes not affect a relatively large percentage of the tran-
scriptome. Furthermore, we observed consistency in the way
genes changed across the two dosages (Table S1; Figures 4B
and 4C). In total, 631 genes were upregulated by either dosage,Cell Repand 401 of these genes were shared across the two concentra-
tions (Figure 4B). When comparing the fold change of these
values, we observed a correlation (Pearson r = 0.967) between
the two ActD treatments, indicating that the degree of change
did not vary significantly at the higher dosage (Figure 4C). There-
fore, it is clear that the 0.25 mg/kg dosage, which is required
for maximal splicing rescue, does not affect significantly more
transcripts compared to the 0.125 mg/kg dosage, although we
anticipate that a larger dosage difference may affect a greater
proportion of genes. The functional categories of genes that
are changed in both ActD treatments are found in Table S2 and
indicated that the gene ontology term ‘‘extracellular matrix’’
had a significant p value (p = 9.22 3 1021).
RNA-seq data were also used to validate our previous findings
that ActD rescued mis-splicing in the HSALR mouse, as well as
identify additional splicing changes that resulted from ActD
treatment. Differential splicing analyses were used to compare
‘‘percent spliced in’’ (PSI or J) values of alternatively spliced
cassette exons between WT and ActD-treated mice (change in
splicing denoted as DJ). In total, 265 skipped exon events
showed evidence of mis-regulation between WT and HSALR
mice (DJ R 0.05, Bayes factor R 5; Table S3). This finding
was consistent with previously published results (Wang et al.,
2012). Of those events, 70 were rescued to some degree with
0.25 mg/kg ActD, 53 events were rescued with 0.125 mg/kg
ActD and 40 showed rescue in both dosage groups. Importantly,
of the 70 events rescued at the 0.25 mg/kg dosage, the majority
demonstrated greater than 50% mis-splicing rescue upon ActD
treatment (Figure 5A). Three events previously examined using
qRT-PCR (Mbnl1, Ldb3, and Atp2a1) demonstrated a clear trend
toward splicing rescue as did three previously unexplored events
(Capzb, Igtb1, and Usp47) (Figure 5B). Interestingly, the gene
ontology term ‘‘alternative splicing’’ was among those with a
low p value for both ActD concentrations (p = 4.00 3 1010) for
gene expression changes (Table S2).
DISCUSSION
Our results demonstrate that ActD, a known transcription inhib-
itor with affinity and specificity for GC-rich DNA (Kamitori and Ta-
kusagawa, 1992), reduces CUG RNA transcript levels in both
DM1 cell and mouse models (Figures 2Aand 2B), and rescues
MBNL1 dependent mis-splicing events in a mouse model (Fig-
ure 3). At low nanomolar concentrations, ActD reduced CUG
levels in HeLa and DM1 cells by 50%, and a similar effect was
observed with a 0.25mg/kg dosage over 5 days in a DM1mouse
model. Importantly, RNA-seq results from ActD treated DM1
mice demonstrated that ActD did not affect transcription glob-
ally; at 0.25 mg/kg less than 5% of genes were altered; however,
multiple mis-spliced events were partially or fully rescued with
this ActD dosage (Figure 5). Taken together, these results sug-
gest that ActD possesses specificity for the CTG/CUG repeats
at this concentration, and furthermore has the ability to reverse
DM1 molecular pathology.
Currently, ActD is most commonly used as a key component in
themultimodal treatmentof several cancer types, includingWilms
tumors in children and gestational trophoblastic neoplasias in
adult women (Hill et al., 2014; Osborne et al., 2011). Standardorts 13, 2386–2394, December 22, 2015 ª2015 The Authors 2389
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Figure 3. Actinomycin D Rescues Mis-
splicing Events in HSALR Mice
(A) qRT-PCR analysis of HSA transgene levels in
HSALR mice treated with PBS and 0.5% DMSO or
indicated dosages of ActD for 5 days. Each circle
represents the transcript levels within vastus muscle
of a single mouse. Mice treated with any of the ActD
dosages exhibited significant reduction of HSA
transgene levels as compared to control treated
mice. Asterisk indicate significance (*p% 0.05).
(B) qRT-PCR analysis of endogenous DMPK levels
(no repeats) in HSALR mice treated with PBS and
0.5%DMSO or indicated dosages of ActD for 5 days.
None of the ActD dosages caused significant
reduction of DMPK levels.
(C–H) Jitterplot representation of various endoge-
nous splicing events perturbed in DM1 mice. Each
symbol represents the splicing outcome for vastus
muscle of a single mouse, while line represents the
average of all experiments.
(C) Clcn1 splicing demonstrates almost complete
rescue by 0.25 mg/kg per day for 5 days. Gel images
of two replicates per condition are demonstrated
below.
(D) In theAtp2a1 event, almost full rescue is observed
by 0.25 mg/kg per day for 5 days.
(E) Mbnl1 auto-regulates exon 5 inclusion, but the
highest ActD dosage only reverses 50% of the
observed mis-splicing in mice.
(F) ActD reverses mis-splicing of the Vps39 exon 3
event completely by 0.25 mg/kg per day for 5 days.
(G and H) Nfix and Ldb3 events both exhibit partial
but significant reversal of mis-splicing upon treat-
ment with ActD.
2390 Cell Reports 13, 2386–2394, December 22, 2015 ª2015 The Authors
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Figure 4. Less Than 5% of Genes Are
Differentially Expressed in Mice upon
Actinomycin D Treatment
(A) MA-plots of 0.125 mg/kg compared to no-
treatment (PBS) controlmice (left) and 0.250mg/kg
compared to no-treatment (PBS) control mice
(right). Gene log2 fold change is plotted against the
mean of normalized counts. Red circles denote
genes with adjusted p values less than 0.1. Points
that do not fall within the window are denoted with
triangles.
(B) Venn diagram depicts the number of differen-
tially expressed genes shared by the two treat-
ments compared to the no-treatment control.
(C) Genes are plotted with the log2 fold change for
mice treated with low (0.125 mg/kg) verses high
(0.250 mg/kg) dose of ActD.dosages of treatment for children and adults vary between 0.015
and 0.045 mg/kg. In this study, the lowest and highest dosages
administered to mice were 0.025 mg/kg and 0.25 mg/kg. To
extrapolate the human equivalent dosage (HED) of this treatment
range, we used a body surface area normalization method, rec-
ommended as the appropriate conversionmethodwhen entering
phase I and II clinical trials (Reagan-Shaw et al., 2008). This
method calculates the HED of a treatment by multiplying the ani-
maldosagebyanappropriate species-specificconversion factor,
orKm,whichhasbeenpreviously established for a number of spe-
cies used as animal models (Freireich et al., 1966). Our results
demonstrated that ActD is able to reduce CUG RNA in mice
with a HED value of 0.002 mg/kg and corrected mis-splicing at
a HED value of 0.02 mg/kg. Both of these concentrations are
below the approved therapeutic range used for Wilms tumors in
standard adult patients (body weight average = 60 kg). Overall,
our findings demonstrate that inhibiting transcription of CTG ex-Cell Reports 13, 2386–2394, Depansions is a promising approach for po-
tential treatment of DM1. It will be inter-
esting to determine if ActD can inhibit
transcription of other GC-rich toxic RNAs
such as CCUG repeats that cause DM2,
CGG repeats that cause FXTAS and
GGGGCC repeats implicated in causing
ALS (Mohan et al., 2014).
We also observed a significant
decrease of cellular foci in our HeLa-
based DM1 model (Figure 2C). However,
we interpreted these data cautiously
because of the noted distinction in how
ActD reduces CUG RNA in HeLa versus
DM1 cellular systems. It is not clear why
the reductionofCUGrepeats byActD rea-
ches a plateau and modestly increases at
higher ActD concentrations in the DM1
patient cells. Another small molecule
could be added to target the remaining
CUG repeats to determine if a cocktail
approach could have a significant impact
on CUG repeat levels. These results com-binedwith previouswork showing that diamidines reduced levels
of CUG repeat RNAs in DM1 cell and mouse models (Coonrod
et al., 2013; Siboni et al., 2015), suggest that targeting transcrip-
tion of expanded CUG repeats and other repeat expansions
should be pursued to develop lead compounds for potential ther-
apeutics for DM and other toxic RNA diseases.
EXPERIMENTAL PROCEDURES
Isothermal Calorimetry Methods
DNA and RNA sequenceswere purchased from Integrated DNA Technologies.
Actinomycin D was dissolved in ITC buffer Stock DNA, RNA, and ActD solu-
tions were prepared by dissolving in ITC buffer (13 PBS, 5 mM MgCl2). The
oligomer samples were then heated to 90C for 5 min followed by cooling on
ice. ITCmeasurements were carried out on aMicroCal titration calorimeter (GE
Healthcare) at 20C. The solution in the cell (the nucleic acid) was stirred at
293 rpm by the syringe during the entire course of the experiment and the
reference power of the instrument was held at 25 mCal/s. ActD was titratedcember 22, 2015 ª2015 The Authors 2391
Figure 5. Numerous Mis-spliced Events Are
Rescued upon Actinomycin D Treatment in
DM1 Mice
(A) Distribution of the average percent rescue
observed for the 70 splicing events that were mis-
regulated in HSALR mice and showed evidence of
rescue in littermate mice treated with 0.25 mg/kg
ActD.
(B) Jitterplot representation of various splicing
events perturbed in HSALR mice that showed evi-
dence of rescue. Each symbol represents the
splicing outcome estimate generated by MISO in
the vastus muscle of a single mouse and the line
represents the 95% confidence interval on that
estimate.in 8 ml injections with a wait time of 300 s between injections. A smaller initial
injection of 4 ml was made after the initial wait time of 60 s to guarantee that
only fully concentrated ActD was injected in subsequent injections. All ITC
data were analyzed using Origin 7.0 software supplied by MicroCal. A non-
linear least-squares fit algorithm was used with a two site, sequential binding
model. One site and two independent sitesmodels were also tested but did not
fit the data as well as the sequential model.
Northern Blot Analysis
Tissue culture methods were performed as previously described (Coonrod
et al., 2013). A total of 1 mg of cellular RNAwas loaded onto a 1% formaldehyde
denaturing agarose gel with 13 MOPS buffer (20 mM MOPS, 8 nM NaOAc,
1 mM EDTA) in northern sample buffer (67% formamide, 21% formaldehyde
solution, 13 MOPS buffer). The gel was run in 13 MOPS buffer at 100 V for
4.5 hr. Gel was transferred to a 0.45 mm nylon Magna membrane (GE) and
the cross-linked using a UV Stratalinker (Stratagene) on the optimal cross-
link setting. Membranes were probed at 55C overnight using radiolabeled
oligos: 50- (CAG)2TCGAG(CAG)4 for CUG repeats in CUG960 and 50-TCCAC-
CACCCTGTTGCTGTAGCCAAATTCG for GAPDH. For DM1 patient-derived2392 Cell Reports 13, 2386–2394, December 22, 2015 ª2015 The Authorscells, the following radiolabeled oligo was used:
50- (CAG)7. Blots were quantified using Image-
Quant (Molecular Dynamics). The relative levels
of RNA were calculated by first normalizing lanes
within the same gel using the GAPDH signal, and
then gels were normalized by setting the levels of
repeats in the untreated cells to 1. Error was deter-
mined by calculating the SD of triplicate data.
Fluorescent Microscopy
Imaging of foci was performed as previously
described (Warf et al., 2009). Briefly, HeLa cells
were plated in six-well plates onto coverslips and
transfected with 500 ng of CUG960 plasmid for
each experiment. After transfection, ActD was
added in the indicated concentrations and the cells
were fixed with 4% PFA 16 hr later. Cells were per-
meabilized, then probed overnight at 37C with a
Cy3 CAG10 probe (IDT, IA). The next night, cells
were probed overnight with the MB1a anti-MBNL1
antibody (1:5000 dilution, MDA Monoclonal Anti-
body Resource) in 13 PBS. Cells were washed
with13PBSand incubatedwithdonkeyanti-mouse
Alexa 488 (1:500 dilution). After beingmounted onto
glassslidesusinghard-setmountingmedia thatcon-
tains DAPI (Vectashield), cells were imaged on an
Olympus Fluoview FV1000 with a Bx61 scope. Nu-
clear foci for each cell were quantified using ImageJ.
The number of cells scored was 35 for the CUG960
transfection, and 33 cells were scored when cells were treated with ActD. F test
analyseswereperformedtodetermine if thedatasetspossessedequalorunequal
variances. Appropriate t test analyses were then performed using Excel.
ActD Treatment of Mice
Mouse handling and experimental procedures were conducted in accordance
with the Association for Assessment and Accreditation of Laboratory Animal
Care. HSALR transgenic mice in line 20b (FVB inbred background) were previ-
ously described (Mankodi et al., 2000). Gender-matched homogeneousHSALR
mice of 6–7 weeks age were treated with ActD at the indicated dose by daily
intraperitoneal injection for 5 days. Control group received PBS with 0.5%
DMSO. Mice were killed 1 day after the final injection and vastus lateralis mus-
cles (quadriceps) were obtained for splicing analysis. RNA extraction, cDNA
preparation, PCR amplification, and analyses on agarose gels using a fluorim-
ager were all performed as previously described (Warf et al., 2009).
qRT-PCR
Quantitative real-time PCR was performed with TaqMan Gene Expression
assays on an ABI PRISM 7900HT Sequence Detection System (Applied
Biosystems) and analyzed using the Quantitative-Comparative (CT) method.
The levels of human skeletal actin (HSA) mRNA and mouse endogenous
DMPK mRNA were normalized to Gtf2b mRNA and displayed graphically as
relative mRNA levels.
RNA-Seq
Whole-tissue RNA was TRIzol extracted from quadricep muscle of two age-
matched mice treated with either no ActD (PBS), 0.125 mg/kg, or 0.25 mg/
kg actinomycin D. For each sample, 10 mg of RNA were prepped, depleted
of rRNA using a Ribo-Zero rRNA removal kit (Epicenter), and used to generate
sequencing libraries using the ScriptSeq v2 kit (Epicenter). After PCR amplifi-
cation, each of the six libraries was combined in equimolar amounts to a total
of 20 nM and submitted for single-end, 75-base pair sequencing on the Illu-
mina Next-Seq 500 massively parallel sequencer at the University of Oregon
Genomics Core Facility. Illumina RNA-sequencing reads were aligned against
the mm10 mouse reference genome with GSNAP, using a splice sites map file
that was generated from Ensemble mm10 gene models (GRCm38.80) and al-
lowing for splicing detection (Wu and Nacu, 2010) (http://research-pub.gene.
com/gmap/). Between 48.5 and 98 million unique reads were acquired for
each sample, of which 84% mapped to the mouse genome. Gene read
counts were generated with HT-Seq (Anders et al., 2015) using the Ensemble
mm10 (GRCm38.80) gene model annotations and used as the input to DE-
Seq2. Differential expression analysis was performed with DESeq2 (Love
et al., 2014) using a FDR = 0.1 as a cutoff for statistical significance. Isoform
abundances were estimated for each HSALR sample and compared to the
pooled average of four wild-type samples (Wang et al., 2012) using MISO
version 0.5.3 (Katz et al., 2010) and the mm10 alternative splicing event anno-
tations provided by the developers of MISO (http://miso.readthedocs.org/en/
fastmiso/). Functional annotations were obtained using DAVID bioinformatics
resources (Huang et al., 2009a, 2009b).
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